Clinical trial
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent…
NCT00081809 · Agenus Inc., Industry · Completed
Key facts
| NCT number | NCT00081809 |
|---|---|
| Title | A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma |
| Official title | A Phase II Trial of Active Specific Immunotherapy in Patients With Indolent Lymphoma Using Autologous Lymphoma-Derived Heat Shock Protein-Peptide Complex (HSPPC-96) |
| Lead sponsor | Agenus Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Follicular, Small Lymphocytic |
| Intervention type | Drug |
| Interventions | autologous human tumor-derived HSPPC-96 |
| Enrollment | 35 |
| Start date | Mar 1, 2000 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Apr 23, 2004 |
| Last update posted | Sep 28, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: